Athyrium Opportunities IV Acquisition 2 LP 13D and 13G filings for RVL Pharmaceuticals plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-11-27 9:24 pm Unchanged |
2023-11-20 | 13D | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% |
0 (Unchanged) |
Filing |
| 2023-10-13 5:28 pm Unchanged |
2023-10-12 | 13D | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% |
0 (Unchanged) |
Filing |
| 2023-09-05 07:45 am Unchanged |
2023-09-05 | 13D | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% |
0 (Unchanged) |
Filing |
| 2022-08-11 3:53 pm Purchase |
2022-08-08 | 13G | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 14.750% |
6,262,242 (+75.10%) |
Filing |
| 2021-10-22 4:27 pm Purchase |
2021-10-12 | 13G | RVL Pharmaceuticals plc RVLPQ |
Athyrium Opportunities IV Acquisition 2 LP | 8,338,202 9.990% |
8,338,202 (New Position) |
Filing |